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Many cellular signaling events are regulated by tyrosine phos-
phorylation and mediated by the opposing actions of protein
tyrosine kinases and phosphatases. Protein tyrosine phosphatases
are emerging as drug targets, but poor cell permeability of in-
hibitors has limited the development of drugs targeting these
enzymes [Tautz L, et al. (2006) Expert Opin Ther Targets 10:157–
177]. Here we developed a method to monitor tyrosine phospha-
tase activity at the single-cell level and applied it to the identiﬁ-
cation of cell-permeable inhibitors. The method takes advantage
of the ﬂuorogenic properties of phosphorylated coumaryl amino
propionic acid (pCAP), an analog of phosphotyrosine, which can be
incorporated into peptides. Once delivered into cells, pCAP pepti-
des were dephosphorylated by protein tyrosine phosphatases,
and the resulting cell ﬂuorescence could be monitored by ﬂow
cytometry and high-content imaging. The robustness and sen-
sitivity of the assay was validated using peptides preferentially
dephosphorylated by CD45 and T-cell tyrosine phosphatase and
available inhibitors of these two enzymes. The assay was applied
to high-throughput screening for inhibitors of CD45, an important
target for autoimmunity and infectious diseases [Hermiston ML,
et al. (2003) Annu Rev Immunol 21:107–137]. We identiﬁed four
CD45 inhibitors that showed activity in T cells and macrophages.
These results indicate that our assay can be applied to primary
screening for inhibitors of CD45 and of other protein tyrosine
phosphatases to increase the yield of biologically active inhibitors.
single-cell assay | peptide substrate
Protein tyrosine phosphatases (PTPs) are important regulatorsof signal transduction and are emerging as drug targets for
common and debilitating human diseases, including cancer, di-
abetes, arthritis, and infectious diseases (1). The transmembrane
PTP CD45, a critical regulator of signaling through the T-cell
receptor (TCR), was one of the ﬁrst PTPs to be considered as
a drug target for treatment of human autoimmune diseases (2).
In addition, inhibitors of PTP-1B and SHP-2 currently are being
sought for therapy of metabolic diseases and cancer, respectively
(3–5). Unfortunately, development of small-molecule inhibitors
of PTPs has been a challenging task. Poor cell permeability of
PTP inhibitors has been a limitation difﬁcult to overcome in later
stages of drug development (5). Several methods to assess in-
tracellular PTP activity are available (6–8), yet no assay has been
able to capture intracellular PTP activity at the single-cell level.
Cell-based PTP assays that work at the single-cell level and are
suited to high-throughput screening might accelerate PTP in-
hibitor development.
In this report we describe the development and optimization
of a method to monitor PTP activity at the single-cell level by
using cell-permeable ﬂuorogenic peptides that, once delivered
into cells, are dephosphorylated by PTPs. The dephosphorylation
of these peptides by PTPs generates a signal that can be monitored
by ﬂow cytometry and high-content imaging. By using peptides
that are preferentially dephosphorylated by selected PTPs, we
tailored our assay to detect intracellular enzyme inhibition by cell-
permeable compounds. The optimized assay was sensitive and
robust and was applied successfully to the screening of libraries for
small-molecule inhibitors of CD45, identifying four inhibitors. As
expected, when incubated with human T cells, all four compounds
led to increased phosphorylation of Lck on tyrosine residues 505
(Y505) and 394 (Y394), primary substrates of CD45 in T cells (2,
9). These compounds also increased signaling through the TCR,
and, consistent with our previous report that CD45 inhibition is
protective against Bacillus anthracis infection (10), they promoted
macrophage viability in a cellular anthrax lethal toxin (LT)
cytotoxicity assay.
Results
Recently, we reported the synthesis of a ﬂuorogenic, phospho-
tyrosine-mimetic amino acid, phosphorylated coumaryl amino
propionic acid (pCAP) (Fig. 1A) (11). The pCAP moiety itself
has minimal ﬂuorescence, but dephosphorylation releases CAP,
which is highly ﬂuorescent. Replacement of phosphotyrosine
with pCAP in known PTP peptide substrates results in efﬁcient
ﬂuorogenic probes of in vitro PTP activity. Peptides containing
the pCAP moiety provide a sensitive, ﬂuorogenic assay that has
been useful in inhibitor screens (12) and combinatorial peptide
substrate libraries (13).
Based on the in vitro utility of these substrates, we set out to
optimize the substrates for intracellular use, reasoning that ﬂu-
orogenic substrates for intracellular PTP activity would be useful
in both identifying and validating inhibitors of PTP activity.
Initially, we synthesized the peptide Ac-EDNE-(pCAP)-TARE-
NH2 (hereafter, peptide 1) based on the sequence surrounding
the activating phosphotyrosine 394 in Lck, a T-cell–speciﬁc
protein tyrosine kinase and a known substrate of the PTPs
CD45, lymphoid tyrosine phosphatase (LYP), and Src ho-
mology region 2 domain-containing phosphatase 1 (SHP-1) (9,
14, 15). Indeed, this peptide was dephosphorylated efﬁciently
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by recombinant CD45, LYP, and SHP-1 in vitro (SI Discussion).
Notably, this peptide was not dephosphorylated by serine/thre-
onine phosphatases, nor was the dephosphorylated peptide
phosphorylated by tyrosine kinases (SI Discussion and Fig. S1).
To provide a proof of principle for the use of these ﬂuorogenic
peptides in cell-based assays, peptide 1 was microinjected into
sea urchin oocytes. As shown in Fig. 1B, intracellular phospha-
tases readily dephosphorylated the peptide. However, peptide
dephosphorylation was inhibited in the presence of the pan-
speciﬁc PTP inhibitor sodium orthovanadate, indicating that
pCAP peptides are dephosphorylated by PTPs once delivered
intracellularly. Delivery of peptide 1 into human Jurkat T cells
was accomplished by electroporation. Again, the peptide was
dephosphorylated readily (within 1 min) by intracellular phos-
phatases (Fig. 1C). Electroporation of cells with the CAP-
containing peptide (Ac-EDNE-(CAP)-TARE-NH2; hereafter,
peptide 1b) provided a positive control, resulting in highly ﬂuo-
rescent cells, whereas electroporation with a peptide containing
the nonﬂuorescent, nonhydrolyzable Et2pCAP moiety (Ac-
EDNE-(Et2pCAP)-TARE-NH2; hereafter, peptide 1c) provided
a minimally ﬂuorescent negative control (Fig. 1C). In addition,
pretreatment of cells with sodium orthovanadate inhibited the
ﬂuorescence of cells electroporated with peptide 1 but had no
effect on the ﬂuorescence of cells incubated with peptide 1b (Fig.
1D), and the inhibition could be detected in a dose-dependent
manner (Fig. 1E). Although efﬁciency of transfection could not
be quantiﬁed precisely for each peptide, incubation with peptides
1, 1b, and 1c induced similar cell lethality. Assuming that the three
peptides have similar intracellular penetration features, these data
suggest that intracellular PTPs dephosphorylate pCAP-containing
peptides, producing a ﬂuorescent signal that can be detected by
both microscopy and ﬂow cytometry. However, these initial
experiments highlighted two challenges to the use of pCAP
peptides for monitoring intracellular PTP activity and inhibition:
(i) the need for a more widely applicable and less invasive method
for introducing peptides into cells, and (ii), the need for PTP-se-
lective peptides rather than peptide sequences that are readily
dephosphorylated by multiple PTPs.
To achieve spontaneous intracellular peptide delivery in mam-
malian cells, we turned to cell-penetrating peptides such as
the antennapedia peptide, polyarginine, and polyarginine with
a lipid tail (Fig. 2A) (16, 17). The addition of both polyarginine
and a lipid tail resulted in the most efﬁcient internalization,
with myristoyl-βAla-(Arg)7-CAP-NH2 (C14-R7-CAP; hereafter
CAP-CPP) providing the optimal combination. Longer lipid
chains did not increase uptake efﬁciency, as shown in Fig. 2B.
Confocal microscopy of cells incubated with CAP-CPP con-
ﬁrmed that the peptide was internalized to the cytosol (Fig. 2B
and Fig. S2).
To design probes selective for one member of the PTP family
of enzymes, we took a two-pronged approach. First, because
the charge and hydrophobicity of surfaces surrounding the cat-
alytic pocket vary considerably among PTPs (15, 18–20), we ex-
plored whether the addition of the polyarginine tag with a lipid
tail restricts the selectivity of the peptides. A cell-penetrating
version of peptide 1 (myristoyl-βAla-(Arg)7-EDNE-(pCAP)-
TARE-NH2; hereafter, SP1) was synthesized. As described ear-
lier, the SP1 peptide sequence is derived from the sequence
surrounding Y394 in Lck, a known biological substrate for SHP-
1, LYP, and CD45 (9, 14, 15). We then analyzed the selectivity of
the probe against a panel of cytosolic PTPs in relation to the
expression levels of the same PTPs in Jurkat T cells (Fig. S2).
The addition of the myristoyl-polyarginine tag virtually elimi-
nated the activity of SHP-1 [which is expressed prominently in
Jurkat T cells (Fig. S2)] and of LYP on this probe in vitro.
However, CD45 retained the ability to hydrolyze this peptide
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Fig. 1. pCAP peptides can be used to monitor intracellular PTP activity. (A) Structure of pCAP, CAP, and Et2pCAP. (B) Images of sea urchin oocytes taken
7 min after microinjection on a ﬂuorescence microscope. Cells were coinjected with rhodamine and pCAP peptide 1 dissolved in DMSO (Upper) or in DMSO
with 10 mM sodium orthovanadate (vanadate) (Lower). (Left and Middle) Fluoresence as detected using a DAPI or rhodamine emission ﬁlter, respectively.
(Right) Phase-contract microscopy. (C) Jurkat T cells were electroporated with 100 μM pCAP peptide 1, CAP peptide 1b, or the nonhydrolyzable Et2pCAP
peptide 1c. Graph shows ﬂuorescence of cells 30 s or 1 min after electroporation. MFI, median ﬂuorescence intensity. (D and E) Inhibition of intracellular pCAP
dephosphorylation by vanadate. (D) Jurkat cells were preincubated for 60 min with 10 mM vanadate or buffer alone. Graphs show ﬂuorescence of cells 1 min
after electroporation with 100 μM pCAP peptide 1 or CAP peptide 1b. (E) Jurkat cells were preincubated for 5 min with increasing concentrations of vanadate.
Graph shows MFI of cells 1 min after electroporation with 100 μM pCAP peptide 1 (open circles). MFI of nonelectroporated cells incubated with 100 μM pCAP
peptide 1 (closed black circle) is shown.
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efﬁciently, as shown in Fig. 2C. T-cell protein tyrosine phospha-
tase (TC-PTP), protein tyrosine phosphatase 1B (PTP1B), he-
matopoietic protein tyrosine phosphatase (HePTP), and vaccinia
H1-related phosphatase (VHR) showed moderate to low activity
on the probe (Fig. 2C). However, in Jurkat T cells the expression
of these enzymes is threefold to more than 10-fold lower than the
expression of CD45 (Fig. S2). Moreover TC-PTP is partly dis-
tributed into the nucleus (Fig. S2), where it would be unavailable
to dephosphorylate the probe. Therefore we reasoned that CD45
likely would be a major contributor to the intracellular dephos-
phorylation of the SP1 probe in Jurkat T cells. In addition, we
explored whether probe selectivity could be achieved by opti-
mizing the peptide sequence based on known substrate-proﬁling
data. We identiﬁed a potential TC-PTP–selective peptide se-
quence from the literature (21). We designed a cell-permeable
analog of this peptide by attaching the myristoyl-polyarginine
tail at the N terminus (myristoyl-βAla-(Arg)7-(PEG)4-REGLN-
(pCAP)-MVLAT-NH2; hereafter, SP2). To minimize possible
interference of the polyarginine tag with the PTP substrate se-
lectivity, we incorporated a 4XPEG spacer between the tag and
the peptide. As illustrated in Fig. S2, this peptide was pre-
dominantly dephosphorylated by TC-PTP, PTP1B, and CD45,
much less so by LYP, HePTP, or VHR, and not at all by SHP-1.
We assessed whether peptide probes are suited to both
quantitative high-content imaging with RAW 264.7 macrophages
and ﬂow cytometry with Jurkat T cells to monitor intracellular
PTP activity. In these experiments a ﬂuorescent positive control
was obtained by substituting CAP for pCAP in the sequence of
SP1 (CAP-SP1). CAP-SP1 was internalized into RAW 264.7
macrophages readily in a dose- and time-dependent manner (Fig.
S3). RAW cells incubated with SP1 also showed a dose-dependent
increase in ﬂuorescence (Fig. S3), which was reduced dramatically
by the addition of sodium orthovanadate (Fig. 2 D and E). The
same results were obtained in Jurkat T cells by ﬂow cytometry, as
shown in Fig. 2F and Fig. S3. To determine the sensitivity of the
assay in detecting lower PTP inhibitor activities, which are closer
to those commonly used in the screening process, we performed
a time-dependent study in which the dephosphorylation re-
action was maintained far from the steady state. In cells in-
cubated with SP1, an incubation time of 10 min enabled robust
detection of phosphatase inhibition by 10 μM vanadate (Fig. S3).
These experiments demonstrate efﬁcient delivery of peptide
probes into mammalian cells as well as hydrolysis of pCAP-
containing peptides, which can be inhibited by the addition
of the pan-speciﬁc PTP inhibitor sodium orthovanadate. After
probe concentration and incubation time were optimized, the
assay was able to detect partial inhibition of intracellular PTPs by
a nonselective PTP inhibitor.
The sensitivity and selectivity of the SP1 probe to intracellular
CD45 activity in the optimized conditions were assessed by
measuring the ﬂuorescence of CD45-positive Jurkat T cells and
CD45-null J45.01 T cells (22) after exposure to the peptide. The
cellular ﬂuorescence caused by peptide dephosphorylation was
signiﬁcantly lower in the CD45-null cells (Fig. 3A), and the
assay was sensitive enough to detect a reduction in peptide
dephosphorylation following a partial knockdown of CD45 ex-
pression in Jurkat T cells using a PTPRC-speciﬁc antisense oli-
gonucleotide (Fig. 3B and Fig. S4). Further validation that the
ﬂuorescent signal seen upon incubation of Jurkat T cells with SP1
is caused by CD45-mediated dephosphorylation was obtained by
coincubating the cells with known cell-permeable inhibitors of
CD45 [NSC 95397 (10), which at 10 μM caused almost 100%
inhibition of CD45 but did not inhibit TC-PTP, PTP1B, LYP,
or HePTP and caused negligible inhibition of VHR], TC-PTP
[compound 8 (23), a very selective inhibitor with an IC50 value of
4.3 nM on TC-PTP, eightfold greater selectivity than PTP1B, and
no activity on CD45, HePTP, LYP, or VHR], or LYP [compound
4 (24), which inhibits LYP and HePTP with IC50 values of 20 μM
and displays ﬁvefold greater selectivity than CD45] (Fig. 3C and
Fig. S4). The signal in the assay was sensitive to inhibition of CD45
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Fig. 2. Single-cell assay for PTP activity using cell-permeable pCAP peptides. (A and B) Flow cytometry analysis of cell-permeable CAP uptake by Jurkat T cells.
(A) Cells were incubated for 1 h with 12.5 μM CAP-R8, C14-R7-CAP (CAP-CPP), medium alone, or non–cell-permeable CAP, and analyzed by FACS. a.u., arbitrary
units. (B) Cells were incubated with 10 μM CAP-CPP, C16-R7-CAP, C18-R7-CAP, C20-R7-CAP, non–cell-permeable CAP, or medium alone for 1 h, and analyzed by
FACS. Inset shows representative image of a Jurkat cell incubated with 10 μM CAP-CPP for 1 h. (C) The cell-permeable probe SP-1 is selective for CD45. In vitro
assay to measure dephosphorylation of 0.1 mM SP-1. Graph shows mean ± SD of relative ﬂuorescence units/s. (D and E) Detection of PTP activity and in-
hibition by high-content imaging. (D) Graph shows average cytoplasmic intensity of RAW 264.7 macrophages incubated for 1 h with 100 μM SP1 or 40 μM
CAP-SP1 and increasing concentrations of vanadate. (E) Representative images of cells from D incubated with SP-1 or CAP-SP1 in the absence or presence of
100 μM vanadate. Fluorescence of CAP and nuclei are pseudocolored blue and green, respectively. (F) Detection of PTP activity and inhibition by ﬂow
cytometry. Jurkat cells were incubated for 1 h with 100 μM SP-1 or CAP-SP1 and increasing concentrations of vanadate or buffer alone.
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but not of TC-PTP (Fig. 3D) or LYP (Fig. S4). The assay also was
unaffected by knockdown of LYP using a PTPN22-speciﬁc anti-
sense oligonucleotide (Fig. S4). Phospho-ﬂow cytometry and
Western blotting analyses further validated the inhibition of CD45
activity by NSC 95397 (Fig. S5). Comparative analysis using the
NSC 95397 compound showed that the performance of the pCAP
assay was at least equivalent, if not superior, to other commonly
used assays in the ﬁeld (Fig. S5). In line with the hypothesis that
TC-PTP is a signiﬁcant contributor to the intracellular dephos-
phorylation of the SP2 probe, the ﬂuorescent signal of SP2 was
sensitive to the TC-PTP inhibitor (Fig. S6). These data indicate
that, if probes with partial in vitro selectivity are available, our
optimized assay can capture the intracellular inhibition of the
subset of PTPs active on the probe.
Having demonstrated the ability to monitor intracellular
phosphatase activity at the single-cell level, we wanted to use this
technology to identify inhibitors of CD45 using a cell-based
screen. To this end, after further conﬁrming that our assay
possesses the reproducibility needed for application in high-
throughput screening (Fig. S7), we screened a library of 44
chemical analogs of the CD45 inhibitor NSC 95397 (10) and 32
compounds with known biological activity selected from the
MicroSource Delivery Systems Spectrum Collection. We used
probe SP1 in Jurkat T cells to screen for cell-permeable inhib-
itors of CD45. Visual inspection of the pattern of cell ﬂuores-
cence enabled easy elimination of ﬂuorescent compounds (Fig.
S7). A parallel screen using the CAP-SP1 probe was performed
to exclude false-positive compounds that affected internalization
of the probe (Fig. S7). However, the current assay does not weed
out endosome/lysosome stabilizers, which would appear as false
positives. Four compounds [L158429 (10), R164259, S349631, and
purpurin] (Fig. 4) were identiﬁed as bona ﬁde hits. The inhibition
of CD45 activity by each of these four compounds was conﬁrmed
in vitro [IC50 values: 2.40 ± 0.63 μM (L158429), 16.88 ± 1.07 μM
(R164259), 9.34 ± 2.07 μM (S349631) and 5.97 ± 1.65 μM
(purpurin); Fig. S8], and their intracellular activity on CD45 in
human T cells was detectable by phospho-ﬂow for phosphoryla-
tion of Lck on Y505 and Y394 (Fig. 5 A–E). The selectivity of
these four compounds was proﬁled against a panel of seven PTPs
and found to be moderate (Table S1). The promiscuous activity of
purpurin was not unexpected in light of previous reports sug-
gesting it acts through an oxidative mechanism (25). However,
when the compounds were tested in a T-cell–activation assay
(induction of CD69 after triggering of the TCR) (Fig. 5F), in line
with their Lck-Y394–inducing activity, they were able to boost
TCR-dependent induction of CD69. We recently reported that
inhibition of CD45 protects macrophages from Bacillus anthracis
infection-induced cell death (10). Therefore we assessed the bi-
ological activity of the compounds in a macrophage viability assay
after exposure to anthrax LT. As expected, the compounds in-
creased resistance of the macrophages to LT-induced lysis in
a dose-dependent manner (Fig. S8). The activity of the com-
pounds in the CD69 and LT assay was somewhat proportional to
their potency on CD45; however, because of the limited selectivity
of these compounds, we cannot exclude the possibility that in-
hibition of other intracellular PTPs expressed in Jurkat T cells,
RAW 264.7 macrophages, or even Bacillus anthracis contributed
to the phenotype observed in cells treated with these compounds.
In summary, through screening with our cell-based ﬂuorogenic
CD45 assay, we identiﬁed four CD45 inhibitors with biological
activity in immune cells.
Discussion
Monitoring the intracellular enzymatic activity of signaling medi-
ators at the single-cell level is increasingly applied in the drug-
discovery ﬁeld to screen chemical libraries (26), but current cell-
based assays do not enable detection of intracellular phosphatase
activity at the single-cell level. In this study we ﬁlled this gap by
developing an assay that takes advantage of the properties of cell-
permeable pCAP peptides, which are more tunable than other
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known ﬂuorogenic PTP substrates. The assay can be applied to
live and ﬁxed cells, and the signal can be detected and measured
by ﬂow cytometry or by image-based high-content systems.
Using a peptide preferentially dephosphorylated by CD45, our
assay could detect the inhibition of intracellular CD45 activity by
cell-permeable compounds. Our data also suggest that pCAP-
based probes preferentially targeting other phosphatases can be
designed based on substrate-proﬁling information. To date, the
mechanisms that govern PTP substrate speciﬁcity are poorly
understood. Consequently the design of substrates that are selec-
tively dephosphorylated by one or a few PTPs is still a challenging
problem. In our assay, the pCAP probe is exposed to the pool of
intracellular PTPs. Therefore, the signal obtained for an inhibitor
targeted to only a subset of the PTPs will be decreased by un-
abated dephosphorylation of the probe by other PTPs. Thus, the
selectivity of the probe is a critical determinant and a limiting
factor of the assay’s performance. The ideal probe should exhibit
inﬁnite selectivity for a particular PTP. Although relatively few
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screening of a library of NSC 95397 analogs (A) and a library of FDA-approved drugs (B). (Upper) Structures of hits. (Lower) Fluorescence of Jurkat T cells
preincubated with test compound (10 μM of NSC 95397 analogs and 50 μM of FDA-approved drugs) or DMSO, followed by incubation with 250 μM SP1 or
25 μM CAP-CPP for 10 min. Green graphs show ﬂuorescence of cells preincubated with 10 μM NSC 95397, followed by incubation with 250 μM SP1.
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Fig. 5. Effect of CD45 inhibitors on immune cell function. (A–D) CD45 inhibitors increase phosphorylation of Lck (Y505) in human T cells. (A–C) Jurkat cells
were preincubated for 30 min with 10 μM, 25 μM, or 50 μM L158429 (A), R164259 (B), or S349631 (C) and 10 μM NSC 95397 or DMSO. (D) Jurkat cells were
preincubated for 30 min with 50 μM, 75 μM, or 100 μM purpurin, 10 μM NSC 95397, or DMSO alone. Graphs show ﬂuorescence of cells after staining with an
anti-pLck (Y505) antibody. (E) CD45 inhibitors increase phosphorylation of Lck (Y394) in human T cells. Jurkat cells were preincubated for 30 min with 25 μM
L158429, 25 μM R164259, 25 μM S349631, 50 μM purpurin, 10 μM NSC 95397, or DMSO alone. Graphs show ﬂuorescence of cells after staining with an anti-
pSrc (Y418) antibody. (F) CD45 inhibitors increase human T-cell activation. Jurkat cells were preincubated for 30 min with 25 μM L158429, 25 μM R164259,
25 μM S349631, 50 μM purpurin, or DMSO alone, followed by stimulation for 4 h with 5 μg/mL anti-CD3. Cell ﬂuorescence was analyzed following staining
with an anti-CD69 antibody.
13976 | www.pnas.org/cgi/doi/10.1073/pnas.1205028109 Stanford et al.
PTP-selective peptides are known so far, substrate proﬁling for
PTPs is gaining momentum, and a variety of approaches have
been developed and applied successfully (21). To increase selec-
tivity further, the chemistry of the tag or of the spacer could be
varied. Promiscuous probes still might be useful to identify or
develop scaffold inhibitors that have low selectivity but score high
in cell permeability, toxicity, and other high-content variables.
We successfully applied the assay to the FACS-based screen-
ing of chemical libraries to identify cell-permeable inhibitors of
CD45. Although CD45 is a relevant drug target in both the au-
toimmunity and infectious disease ﬁelds (2, 10), only a few cell-
permeable inhibitors of CD45 are available (27). In this study we
identiﬁed four inhibitors of CD45, one of which is a compound
approved by the Food and Drug Administration. These com-
pounds displayed variable and overall limited selectivity for CD45,
but all were effective at inhibiting pathways downstream CD45 in
immune cells. These data demonstrate that the use of our assay in
a primary screening effectively enriches for cell-permeable PTP
inhibitors with biological activity. However, they also highlight an
important limitation: In its current version, our assay is mostly
blind to the selectivity of the compounds—which, together with
cell permeability, is a known pitfall of PTP inhibitor discovery. In
the future we envision multiplexing the assay using probes
preferentially dephosphorylated by different PTPs to identify
inhibitors with desirable selectivity proﬁles.
The pCAP-based PTP assay is particularly suited for primary
or secondary screening of chemical libraries by high-throughput
ﬂow cytometry because of the high sensitivity of the FACS ap-
proach (28). Our assay could complement phospho-ﬂow or other
cell-based assays by directly monitoring the effect of the com-
pound on intracellular enzymatic activity. In addition, it offers
a unique advantage when the substrate of the phosphatase is
unknown, and/or a suitable phospho-speciﬁc antibody is not
available, and/or the known substrate can be dephosphorylated
by additional phosphatases.
Materials and Methods
Peptides. The sequences of all peptides used in this study are listed in Table S2.
Peptide synthesis is described in SI Materials and Methods.
Flow Cytometry-Based Assays. For the cell-permeable pCAP-peptide–based
assays, Jurkat cells were incubated in 96-well plates at a concentration of 1 ×
106 cells/100 μL in RPMI medium containing 0.5% FBS, without phenol red.
After incubation with peptide for the indicated times, cells were washed in
ﬂow cytometry buffer (HBSS without Ca2+ and Mg2+, with 5 mM EDTA and
2.5 mg/mL BSA) with 10 mM sodium orthovanadate, ﬁxed in 1% parafor-
maldehyde (wt/vol) at room temperature for 15 min, and stained with LIVE/
DEAD Fixable Red or Near-IR Dead Cell Stain Kits (Invitrogen) according to the
manufacturer’s instructions. Cell ﬂuorescence was monitored by ﬂow cytom-
etry using a BD LSR II or FACSAria (BD Biosciences), exciting with the UV laser
at 355 nm or the violet laser at 407 nm, respectively. pCAP/CAP ﬂuorescence
was detected with DAPI emission ﬁlters. Dephosphorylation of the SP1 probe
also could be monitored using a BD FACSCanto II with excitation with the
violet laser at 405 nm and detection with a Paciﬁc Blue emission ﬁlter.
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